Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer

被引：10

作者：

Chamberlain, Bruce H. ^{[1
]}

Rhiner, Michelle ^{[2
]}

Slatkin, Neal E. ^{[3
,4
]}

Stambler, Nancy ^{[5
]}

Israel, Robert J. ^{[6
]}

机构：

[1] Genesis Healthcare, Davenport, IA 52803 USA

[2] Loma Linda Univ Hlth, Dept Family Med, Loma Linda, CA 92350 USA

[3] Univ Calif Riverside, Sch Med, Riverside, CA 92507 USA

[4] Salix Pharmaceut, Bridgewater, NJ 08807 USA

[5] Progen Pharmaceut Inc, New York, NY 10006 USA

[6] Bausch Hlth US LLC, Bridgewater, NJ 08807 USA

来源：

PAIN MANAGEMENT | 2020年 / 10卷 / 02期

关键词：

cancer; constipation; methylnaltrexone; mu-receptor; opioids; CHRONIC NONCANCER PAIN; INDUCED DELAY; PREVALENCE; SURVIVAL; EFFICACY; MORPHINE; RECEPTOR; IMPACT;

D O I：

10.2217/pmt-2019-0045

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Aim: To evaluate methylnaltrexone for opioid-induced constipation in patients with and without cancer. Methods: This post hoc analysis comprises two Phase III, multicenter, double-blind, randomized studies of advanced-illness patients who received methylnaltrexone subcutaneous injection or placebo. Results: Significantly more patients treated with methylnaltrexone than placebo experienced laxation within 4 (cancer = 55.5 vs 15.5%; noncancer = 55.6 vs 12.8%) and 24 (cancer = 64.7 vs 29.8%; noncancer = 64.4 vs 30.8%) h after the first dose (p < 0.01 vs placebo). Regardless of cancer status, methylnaltrexone reduced median time to laxation and improved constipation relief without impacting opioid analgesia or withdrawal symptoms. Conclusion: Methylnaltrexone provided significant improvements in opioid-induced constipation over placebo in advanced-illness patients with and without cancer. Clinical trial registration numbers: study 301: NCT00401362; study 302: NCT00402038.

引用

页码：73 / 84

页数：12

共 37 条

[1] [Anonymous], 2018, REL PACK INS
[2] [Anonymous], 1996, CATALOGUE HLTH INDIC, P1
[3] The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)
Bell, Timothy J.
Panchal, Sunil J.
Miaskowski, Christine
Bolge, Susan C.
Milanova, Tsveta
Williamson, Russell
[J]. PAIN MEDICINE, 2009, 10 (01) : 35 - 42
[4] Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension
Bull, Janet
Wellman, Charles V.
Israel, Robert J.
Barrett, Andrew C.
Paterson, Craig
Forbes, William P.
[J]. JOURNAL OF PALLIATIVE MEDICINE, 2015, 18 (07) : 593 - 600
[5] Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation
Camilleri, M.
Drossman, D. A.
Becker, G.
Webster, L. R.
Davies, A. N.
Mawe, G. M.
[J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (10) : 1386 - 1395
[6] Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care
Candy, Bridget
Jones, Louise
Vickerstaff, Victoria
Larkin, Philip J.
Stone, Patrick
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (06):
[7] Gastrointestinal side effects in chronic opioid users: results from a population-based survey
Cook, S. F.
Lanza, L.
Zhou, X.
Sweeney, C. T.
Goss, D.
Hollis, K.
Mangel, A. W.
Fehnel, S. E.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (12) : 1224 - 1232
[8] Glare Paul, 2006, Am J Hosp Palliat Care, V23, P229, DOI 10.1177/1049909106289068
[9] Gupta Shaloo, 2015, J Opioid Manag, V11, P325, DOI 10.5055/jom.2015.0282
[10] Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer
Janku, F.
Johnson, L. K.
Karp, D. D.
Atkins, J. T.
Singleton, P. A.
Moss, J.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (11) : 2032 - 2038

← 1 2 3 4 →